Paper
Document
Download
Flag content
4

Visualization of reactive astrocytes in living brain of Alzheimer’s disease patient

Authors
Nam M,Ko Hy
Lee S,Young Park,Hyeon Sj,Won W,Kim Sy,Jo Hh,Jae Chung,Han Yan,Lee G,Young‐Tae Ju,Stein Td,Moonkyoo Kong,Lee H,Jun Lee,Sung‐Kwun Oh,Jongsuk Chun,Park Kd,Ryu H,Miyong Yun,Lee Cj,Min‐Ho Nam,Heung Ko,Sangwon Lee,Yongmin Park,Seung Hyeon,Woojin Won,Seon Kim,Han Jo,Jee-In Chung,Young-Eun Han,Gwan‐Ho Lee,Yeon Ju,Thor Stein,Mingyu Kong,Hyunbeom Lee,Seung Lee,Soo‐Jin Oh,Joong‐Hyun Chun,Ki Park,Hoon Ryu,Mijin Yun,Sang‐Won Lee,Yeonha Ju
+43 authors
,C. Lee
Published
Apr 14, 2021
Show more
Save
TipTip
Document
Download
Flag content
4
TipTip
Save
Document
Download
Flag content

Abstract

Abstract An early appearance of reactive astrocytes is a hallmark of Alzheimer’s disease (AD) 1,2 , providing a substrate for early diagnostic neuroimaging targets. However, there is no clinically validated neuroimaging probe to visualize the reactive astrogliosis in the human brain in vivo . Here, we report that PET/CT imaging with 11 C-acetate and 18 F-fluorodeoxyglucose ( 18 F-FDG) functionally visualizes the reactive astrocyte-mediated neuronal hypometabolism in the brains with neuroinflammation and AD. We demonstrate that reactive astrocytes excessively absorb acetate through elevated monocarboxylate transporter-1 (MCT1), leading to aberrant GABA synthesis and release which suppresses neuronal glucose uptake through decreased glucose transporter-3 (GLUT3) in both animal and human brains. We propose the non-invasive functional PET/CT imaging for astrocytic acetate-hypermetabolism and neuronal glucose-hypometabolism as an advanced diagnostic strategy for early stages of AD.

Paper PDF

This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.